How to Take Vigabatrin: Dosing and Vision Monitoring
Vigabatrin is an irreversible GABA-transaminase inhibitor.Dosing is determined by indication,age,weight,and renal function—there is no single fixed schedule.
Refractory complex partial seizures(adjunctive)
Adults≥17 y:start 500mg twice daily(1000mg/day);increase total daily dose by 500mg weekly per response;recommended maintenance 1500mg twice daily(3000mg/day).6000mg/day gave no extra benefit and more adverse events.
Children 2–16 y by weight(each“per dose”,twice daily):10–15kg start 175mg,maint 525mg;>15–20kg start 225mg,maint 650mg;>20–25kg start 250mg,maint 750mg;>25–60kg start 250mg,maint 1000mg;>60kg use adult dosing.
Adjust weekly;withdraw if no substantial benefit within 3 months.
Infantile spasms(monotherapy,1 mo–2 y)
Start 50mg/kg/day in 2 divided doses(25mg/kg per dose);
Titrate by 25–50mg/kg/day every 3 days;
Max 150mg/kg/day(75mg/kg per dose,BID);
Stop if no clear benefit in 2–4 weeks,or earlier if treatment failure is evident.
Powder for oral solution
Empty one 500mg sachet into a clean cup,add 10mL cool or room-temperature water per sachet,final concentration 50mg/mL;measure with a 3mL or 10mL oral dosing syringe—not household spoons;prepare fresh each time,discard remainder;discard if not clear and particle-free.With or without food.
Renal impairment
Primarily renally cleared:CrCl 50–80mL/min reduce 25%;30–50mL/min reduce 50%;10–30mL/min reduce 75%;dialysis data insufficient.
Tapering—never abrupt
Adult CPS:reduce 1000mg/day weekly;
Larger pediatric CPS:reduce~1/3 of daily dose weekly over~3 weeks;
Infantile spasms:reduce 25–50mg/kg/day every 3–4 days;
Abrupt withdrawal risks withdrawal seizures and status epilepticus.
Boxed warning—permanent vision loss
Vigabatrin causes progressive bilateral concentric visual field constriction,sometimes tunnel vision and reduced acuity;risk rises with dose and cumulative exposure,no risk-free exposure,and may worsen after discontinuation.Required eye assessments:
Baseline(no later than 4 weeksafter starting)
At least every 3 monthsduring therapy
3–6 months after stopping
Use automated threshold perimetry when feasible;ERG,OCT,and dilated indirect ophthalmoscopy for infants or non-cooperative patients.
Also monitor somnolence/fatigue,anemia,peripheral neuropathy,weight gain,edema,suicidal ideation/behavior,and infant MRI signal changes.
Bottom line:lowest effective dose,shortest exposure;if benefit is not achieved,taper out rather than pushing dose.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)